Apr 17, 2026
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home SettingVIEW RELEASE
Apr 08, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress ReactionsVIEW RELEASE
Apr 01, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Apr 17, 2026 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.15
CHANGE
0.08 (7.48%)
